Research analysts at Deutsche Bank started coverage on shares of Express Scripts (NASDAQ:ESRX) in a report released on Monday, Marketbeat.com reports. The brokerage set a “buy” rating and a $75.00 price target on the stock. Deutsche Bank’s target price indicates a potential upside of 10.04% from the company’s previous close.

A number of other equities analysts have also recently issued reports on the stock. ValuEngine cut shares of Express Scripts from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Robert W. Baird restated a “hold” rating and set a $56.00 target price on shares of Express Scripts in a research report on Friday, September 1st. Jefferies Group set a $72.00 target price on shares of Express Scripts and gave the stock a “buy” rating in a research report on Tuesday, August 29th. Raymond James Financial restated an “underperform” rating on shares of Express Scripts in a research report on Monday, October 9th. Finally, Zacks Investment Research lowered shares of Express Scripts from a “buy” rating to a “sell” rating in a research report on Tuesday, October 24th. Six investment analysts have rated the stock with a sell rating, ten have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $70.67.

Express Scripts (ESRX) traded up $3.75 during mid-day trading on Monday, reaching $68.16. 8,791,554 shares of the company were exchanged, compared to its average volume of 4,116,816. The stock has a market capitalization of $36,480.00, a P/E ratio of 9.42, a P/E/G ratio of 0.95 and a beta of 0.88. Express Scripts has a 52-week low of $55.80 and a 52-week high of $77.25. The company has a current ratio of 0.73, a quick ratio of 0.61 and a debt-to-equity ratio of 0.86.

Express Scripts (NASDAQ:ESRX) last released its quarterly earnings data on Tuesday, October 24th. The company reported $1.90 EPS for the quarter, hitting analysts’ consensus estimates of $1.90. The firm had revenue of $24.68 billion for the quarter, compared to the consensus estimate of $25.68 billion. Express Scripts had a net margin of 3.64% and a return on equity of 25.46%. The firm’s revenue was down 2.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.74 earnings per share. analysts predict that Express Scripts will post 7.01 earnings per share for the current year.

In other news, VP Phyllis S. Anderson sold 578 shares of the company’s stock in a transaction on Friday, September 8th. The shares were sold at an average price of $63.13, for a total value of $36,489.14. Following the completion of the transaction, the vice president now directly owns 10,530 shares in the company, valued at $664,758.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Timothy C. Wentworth purchased 8,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 31st. The stock was bought at an average cost of $61.13 per share, for a total transaction of $489,040.00. Following the completion of the acquisition, the chief executive officer now directly owns 98,628 shares of the company’s stock, valued at $6,029,129.64. The disclosure for this purchase can be found here. Insiders sold 5,121 shares of company stock valued at $325,920 over the last 90 days. Insiders own 0.68% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Nordea Investment Management AB raised its holdings in shares of Express Scripts by 1.4% during the second quarter. Nordea Investment Management AB now owns 7,116,445 shares of the company’s stock worth $454,314,000 after purchasing an additional 97,953 shares during the period. First Trust Advisors LP increased its holdings in shares of Express Scripts by 25.3% in the 2nd quarter. First Trust Advisors LP now owns 708,955 shares of the company’s stock worth $45,260,000 after acquiring an additional 143,163 shares during the period. Van ECK Associates Corp increased its holdings in shares of Express Scripts by 5.1% in the 3rd quarter. Van ECK Associates Corp now owns 506,511 shares of the company’s stock worth $32,072,000 after acquiring an additional 24,728 shares during the period. Lazard Asset Management LLC increased its holdings in shares of Express Scripts by 81.8% in the 2nd quarter. Lazard Asset Management LLC now owns 112,666 shares of the company’s stock worth $7,192,000 after acquiring an additional 50,707 shares during the period. Finally, Legal & General Group Plc increased its holdings in shares of Express Scripts by 1.7% in the 2nd quarter. Legal & General Group Plc now owns 3,654,765 shares of the company’s stock worth $233,323,000 after acquiring an additional 62,263 shares during the period. 88.44% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Express Scripts (ESRX) Now Covered by Analysts at Deutsche Bank” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/12/04/express-scripts-esrx-now-covered-by-analysts-at-deutsche-bank.html.

About Express Scripts

Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).

Analyst Recommendations for Express Scripts (NASDAQ:ESRX)

Receive News & Ratings for Express Scripts Holding Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts Holding Company and related companies with MarketBeat.com's FREE daily email newsletter.